WEBULL

Ionis Pharmaceuticals (IONS) Trial Setback Sparks Scrutiny, Is The 38% Undervaluation Case Still Credible?

Simply Wall St · 1d ago

Ionis Pharmaceuticals (IONS) is under renewed scrutiny after reporting that its late stage CARDIO TTRansform trial for eplontersen with AstraZeneca did not meet the primary efficacy endpoint, triggering a sharp share price reaction and a shareholder investigation.

See our latest analysis for Ionis Pharmaceuticals.

The eplontersen trial failure and shareholder investigation come after a sharp shift in momentum for Ionis Pharmaceuticals, with the share price down 26.10% over 30 days and 29.02% year to date, even as the 1 year total shareholder return is 33.86%. Recent news also includes dosing the first participant in the ASCEND study of ION337 for Dravet syndrome.

If you are reassessing your exposure to specialist drug developers after Ionis Pharmaceuticals' trial setback, it could be an opportunity to scan other healthcare focused options using our screener for 39 healthcare AI stocks

After Ionis Pharmaceuticals' sharp pullback and the eplontersen setback, some investors might see a reset, while others prefer to wait for clearer traction. So how does the current price stack up against the fundamentals?

Most Popular Narrative: 38.5% Undervalued

Compared with Ionis Pharmaceuticals' last close at $56.55, the most followed narrative anchors on a fair value of $92.00, framing the recent pullback as a sizable discount that still depends on ambitious execution.

The rapid revenue growth and positive launch trajectory for Tryngolza in familial chylomicronemia syndrome (FCS), along with the imminent launch of Donidalorsen for HAE and multiple late stage pipeline assets reading out or launching by 2027, are set to drive sustained, stepwise increases in top line revenue and operating leverage as Ionis transitions from R&D heavy to commercial stage. Expanding addressable patient populations from rare diseases to larger segments like severe hypertriglyceridemia, combined with favorable physician feedback and significant unmet need, position Ionis to capture substantial market share and revenue growth from trends tied to the rise in chronic disease and an aging population.

Read the complete narrative.

Want to see what is baked into that $92.00 fair value for Ionis Pharmaceuticals? The core narrative leans on rapid revenue compounding, a margin swing into solid profitability and a rich future earnings multiple that is usually reserved for high growth franchises. Curious which specific growth, profitability and valuation assumptions have to line up to keep that discount in place? Read on to unpack the full narrative behind these numbers.

Result: Fair Value of $92.00 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the bullish Ionis Pharmaceuticals story could be challenged if key late stage approvals slip or pricing pressure in broader indications undercuts the earnings and margin outlook that underpins $92.00.

Find out about the key risks to this Ionis Pharmaceuticals narrative.

Another View: What Ionis Pharmaceuticals Looks Like On Sales Based Valuation

The fair value of $92.00 rests on long term earnings assumptions and a rich future P/E. On current sales though, Ionis Pharmaceuticals trades on a P/S of 8.8x, compared with a peer average of 7.3x and a fair ratio of 5.4x. That gap suggests investors are already paying up. How comfortable are you with that?

See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGS:IONS P/S Ratio as at Jul 2026
NasdaqGS:IONS P/S Ratio as at Jul 2026

Next Steps

With sentiment on Ionis Pharmaceuticals split after the recent trial news, this is a good moment to look through the data yourself and decide quickly where you stand before attention shifts to other opportunities, starting with the 3 key rewards

Looking for more ideas beyond Ionis Pharmaceuticals?

If you want to stay ahead of the next wave of opportunities instead of reacting after the fact, use these focused stock lists to widen your watchlist smartly.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.